FDA proposes faster route for individualized genetic medicines

The FDA published a proposed regulatory approach that would allow approval of therapies for ultra‑rare disorders when there is a scientifically supported plausible mechanism linking the therapy to the genetic defect. Agency leaders framed the change as a move to enable bespoke interventions — including gene‑editing and antisense oligonucleotide treatments — in cases where conventional trials are infeasible. Federal officials highlighted a recent single‑patient program at the Children’s Hospital of Philadelphia as a practical trigger for the policy and as evidence that individualized approaches can be replicated. Regulators intend the pathway to apply when molecular understanding of disease and therapeutic action are robust enough to predict benefit without large randomized studies. The proposal explicitly targets conditions with extremely small patient counts or many distinct causal variants that would otherwise demand dozens of separate trials. Stakeholders from academia and hospital systems praised the potential speed and cost benefits, while some legal and bioethics experts warned against scope creep into more common indications. The agency said the framework could be used alongside existing tools, not to replace conventional trials where those remain appropriate. Officials signaled that applications leveraging the pathway will face targeted safety and manufacturing scrutiny tailored to single‑patient or small‑cohort programs. If finalized, reviewers expect a rise in template‑based submissions that adapt a validated molecular design across related mutation classes. The proposal therefore aims to convert molecular templates into an operational regulatory playbook for developers and clinicians. Implementation details — including evidentiary thresholds, post‑market obligations, and payer engagement — will determine how quickly patients see therapies outside research settings.